Advances in genomic research on hepatitis C virus with a useful tool, replicon system

Mitsuyasu Nakamura, Hidetsugu Saito, Toshifumi Hibi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The research for hepatitis C virus (HCV) has long delayed by missing of in vitro culture system. Since the development of replicon system, a replication system of subgenomic HCV RNAs in a hepatoma cell line, has been reported, many virological and clinical findings have been discovered. Recently, in addition of subgenomic replication system, hepatitis C virus full-length RNA replication has been possible, and a few cell culture systems producing viral particles have been produced. These developments enabled us to investigate the life cycle or intracellular circumstance of HCV production. By screening of newly synthesized drugs with this replicon system, several possible medicines have been established and clinical researches are now running. Among them, VX950 and SCH503034 are nearest to clinical use. Other possible agents for reducing viral replication such as cyclophyllin inhibitors, inhibitors of sphingomyelin synthesis, HMG-CoA reductase inhibitors, or RNA-dependent RNA polymerase inhibitors have been also investigated. Furthermore the mechanism for development of hepatocellular carcinoma in the HCV infected liver has been vigorously studied using the HCV replicon system.

Original languageEnglish
Pages (from-to)75-83
Number of pages9
JournalKeio Journal of Medicine
Volume57
Issue number2
DOIs
Publication statusPublished - 2008 Jun

Fingerprint

Replicon
Hepacivirus
Research
Hepatocellular Carcinoma
RNA
RNA Replicase
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sphingomyelins
Reducing Agents
Life Cycle Stages
Virion
Cell Culture Techniques
Cell Line
Liver
Pharmaceutical Preparations

Keywords

  • Hepatitis C virus
  • Lipid raft
  • Rb
  • Replicon
  • VX950

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in genomic research on hepatitis C virus with a useful tool, replicon system. / Nakamura, Mitsuyasu; Saito, Hidetsugu; Hibi, Toshifumi.

In: Keio Journal of Medicine, Vol. 57, No. 2, 06.2008, p. 75-83.

Research output: Contribution to journalArticle

@article{c942f8131af84ceebf1950cdeeb37f0a,
title = "Advances in genomic research on hepatitis C virus with a useful tool, replicon system",
abstract = "The research for hepatitis C virus (HCV) has long delayed by missing of in vitro culture system. Since the development of replicon system, a replication system of subgenomic HCV RNAs in a hepatoma cell line, has been reported, many virological and clinical findings have been discovered. Recently, in addition of subgenomic replication system, hepatitis C virus full-length RNA replication has been possible, and a few cell culture systems producing viral particles have been produced. These developments enabled us to investigate the life cycle or intracellular circumstance of HCV production. By screening of newly synthesized drugs with this replicon system, several possible medicines have been established and clinical researches are now running. Among them, VX950 and SCH503034 are nearest to clinical use. Other possible agents for reducing viral replication such as cyclophyllin inhibitors, inhibitors of sphingomyelin synthesis, HMG-CoA reductase inhibitors, or RNA-dependent RNA polymerase inhibitors have been also investigated. Furthermore the mechanism for development of hepatocellular carcinoma in the HCV infected liver has been vigorously studied using the HCV replicon system.",
keywords = "Hepatitis C virus, Lipid raft, Rb, Replicon, VX950",
author = "Mitsuyasu Nakamura and Hidetsugu Saito and Toshifumi Hibi",
year = "2008",
month = "6",
doi = "10.2302/kjm.57.75",
language = "English",
volume = "57",
pages = "75--83",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - Advances in genomic research on hepatitis C virus with a useful tool, replicon system

AU - Nakamura, Mitsuyasu

AU - Saito, Hidetsugu

AU - Hibi, Toshifumi

PY - 2008/6

Y1 - 2008/6

N2 - The research for hepatitis C virus (HCV) has long delayed by missing of in vitro culture system. Since the development of replicon system, a replication system of subgenomic HCV RNAs in a hepatoma cell line, has been reported, many virological and clinical findings have been discovered. Recently, in addition of subgenomic replication system, hepatitis C virus full-length RNA replication has been possible, and a few cell culture systems producing viral particles have been produced. These developments enabled us to investigate the life cycle or intracellular circumstance of HCV production. By screening of newly synthesized drugs with this replicon system, several possible medicines have been established and clinical researches are now running. Among them, VX950 and SCH503034 are nearest to clinical use. Other possible agents for reducing viral replication such as cyclophyllin inhibitors, inhibitors of sphingomyelin synthesis, HMG-CoA reductase inhibitors, or RNA-dependent RNA polymerase inhibitors have been also investigated. Furthermore the mechanism for development of hepatocellular carcinoma in the HCV infected liver has been vigorously studied using the HCV replicon system.

AB - The research for hepatitis C virus (HCV) has long delayed by missing of in vitro culture system. Since the development of replicon system, a replication system of subgenomic HCV RNAs in a hepatoma cell line, has been reported, many virological and clinical findings have been discovered. Recently, in addition of subgenomic replication system, hepatitis C virus full-length RNA replication has been possible, and a few cell culture systems producing viral particles have been produced. These developments enabled us to investigate the life cycle or intracellular circumstance of HCV production. By screening of newly synthesized drugs with this replicon system, several possible medicines have been established and clinical researches are now running. Among them, VX950 and SCH503034 are nearest to clinical use. Other possible agents for reducing viral replication such as cyclophyllin inhibitors, inhibitors of sphingomyelin synthesis, HMG-CoA reductase inhibitors, or RNA-dependent RNA polymerase inhibitors have been also investigated. Furthermore the mechanism for development of hepatocellular carcinoma in the HCV infected liver has been vigorously studied using the HCV replicon system.

KW - Hepatitis C virus

KW - Lipid raft

KW - Rb

KW - Replicon

KW - VX950

UR - http://www.scopus.com/inward/record.url?scp=47249127753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249127753&partnerID=8YFLogxK

U2 - 10.2302/kjm.57.75

DO - 10.2302/kjm.57.75

M3 - Article

VL - 57

SP - 75

EP - 83

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -